Success Metrics

Clinical Success Rate
33.3%

Based on 4 completed trials

Completion Rate
33%(4/12)
Active Trials
1(7%)
Results Posted
225%(9 trials)
Terminated
8(53%)

Phase Distribution

Ph phase_2
5
33%
Ph phase_4
2
13%
Ph phase_3
4
27%
Ph phase_1
2
13%

Phase Distribution

2

Early Stage

5

Mid Stage

6

Late Stage

Phase Distribution13 total trials
Phase 1Safety & dosage
2(15.4%)
Phase 2Efficacy & side effects
5(38.5%)
Phase 3Large-scale testing
4(30.8%)
Phase 4Post-market surveillance
2(15.4%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

33.3%

4 of 12 finished

Non-Completion Rate

66.7%

8 ended early

Currently Active

1

trials recruiting

Total Trials

15

all time

Status Distribution
Active(1)
Completed(4)
Terminated(8)
Other(2)

Detailed Status

Terminated8
Completed4
unknown2
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
15
Active
1
Success Rate
33.3%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (15.4%)
Phase 25 (38.5%)
Phase 34 (30.8%)
Phase 42 (15.4%)

Trials by Status

active_not_recruiting17%
unknown213%
completed427%
terminated853%

Recent Activity

1 active trials
Showing 5 of 15
terminatedphase_3

Study to Evaluate the Effect of GBT440 on TCD in Pediatrics With Sickle Cell Disease

NCT04218084
active_not_recruitingphase_2

Assessing Physical Function in Sickle Cell Patients Taking Voxelotor

NCT06023199
terminatedphase_2

The Effect of Voxelotor on Cerebral Hemodynamic Response in Children With Sickle Cell Anemia

NCT05018728
terminatedphase_3

Study to Assess the Effect of Long-term Treatment With Voxelotor in Participants Who Have Completed Treatment in Study GBT440-031

NCT03573882
terminatedphase_3

Open-Label Extension of Voxelotor

NCT04188509
View all 15 trials

Clinical Trials (15)

Showing 15 of 15 trials
NCT04218084Phase 3

Study to Evaluate the Effect of GBT440 on TCD in Pediatrics With Sickle Cell Disease

Terminated
NCT06023199Phase 2

Assessing Physical Function in Sickle Cell Patients Taking Voxelotor

Active Not Recruiting
NCT05018728Phase 2

The Effect of Voxelotor on Cerebral Hemodynamic Response in Children With Sickle Cell Anemia

Terminated
NCT03573882Phase 3

Study to Assess the Effect of Long-term Treatment With Voxelotor in Participants Who Have Completed Treatment in Study GBT440-031

Terminated
NCT04188509Phase 3

Open-Label Extension of Voxelotor

Terminated
NCT02850406Phase 2

Study to Evaluate the Effect of GBT440 in Pediatrics With Sickle Cell Disease

Terminated
NCT04335721Phase 1

A Voxelotor for Sickle Cell Anemia Patients at Highest Risk for Progression of Chronic Kidney Disease

Terminated
NCT05981365Phase 1

Voxelotor CYP and Transporter Cocktail Interaction Study

Completed
NCT04724421

Expanded Access Protocol for Adults and Pediatric Patients With Sickle Cell Disease Who Have No Alternative Treatment Options

Unknown
NCT05289570Phase 2

Voxelotor for Improving Oxygen Saturation in Adults

Terminated
NCT04400487Phase 4

Actigraphy Improvement With Voxelotor (ActIVe) Study

Completed
NCT04247594Phase 2

Dose Escalation Study to Evaluate the Safety, Tolerability, PK and PD of Voxelotor in Patients With SCD

Terminated
NCT03036813Phase 3

Study to Evaluate the Effect of Voxelotor Administered Orally to Patients With Sickle Cell Disease (GBT_HOPE)

Completed
NCT03943615

Expanded Access to Voxelotor for Patients With Sickle Cell Disease Who Have No Alternative Treatment Options

Unknown
NCT04581356Phase 4

Voxelotor Sickle Cell Exercise Study

Completed

All 15 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
15